<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208466</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001046</org_study_id>
    <nct_id>NCT02208466</nct_id>
  </id_info>
  <brief_title>Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients</brief_title>
  <official_title>Effects of Contralesional Repetitive Magnetic Stimulation Combined With Fluoxetine on Motor Recovery in Acute Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spaulding Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spaulding Rehabilitation Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study investigator's aim to assess the effect of a type of non-invasive brain
      stimulation technique called repetitive transcranial magnetic stimulation (rTMS) in
      conjunction with fluoxetine on motor recovery after stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Motor Function</measure>
    <time_frame>Measured over 90 days</time_frame>
    <description>We will measure motor function using behavioral tasks (ex. jebsen taylor test, purdue pegboard, range of motion) before and after stimulation sessions at three different time-points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in cortical excitability measures</measure>
    <time_frame>Measured over 90 days</time_frame>
    <description>We will measure cortical excitability using single-pulsed transcranial magnetic stimulation (TMS) before and after stimulation at three different time-points.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Stroke</condition>
  <condition>Motor Function</condition>
  <arm_group>
    <arm_group_label>Active rTMS/active fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS/active fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS/placebo fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Repetitive Transcranial Magnetic Stimulation (rTMS)</intervention_name>
    <description>Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.</description>
    <arm_group_label>Active rTMS/active fluoxetine</arm_group_label>
    <other_name>magnetic stimulation, Magstim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.</description>
    <arm_group_label>Active rTMS/active fluoxetine</arm_group_label>
    <arm_group_label>Sham rTMS/active fluoxetine</arm_group_label>
    <other_name>Prozac, Sarafem, Ladose, Fontex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.</description>
    <arm_group_label>Sham rTMS/active fluoxetine</arm_group_label>
    <arm_group_label>Sham rTMS/placebo fluoxetine</arm_group_label>
    <other_name>Magstim, magnetic stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Fluoxetine</intervention_name>
    <description>Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.</description>
    <arm_group_label>Sham rTMS/placebo fluoxetine</arm_group_label>
    <other_name>Prozac, Sarafem, Ladose, Fontex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic infarction within the past 2 years post event that has caused hemiparesis or
             hemiplegia, as self-reported and/or confirmed by medical record.

          -  Older than 18 years old.

          -  Upper extremity weakness defined as a score of &gt;11 and â‰¤56 on the arm motor Fugl-Mayer
             motor scale.

          -  Minimal pre-stroke disability defined as a score of &lt;3 in the Modified Rankin Scale.

          -  Subjects need to be able to follow directions and participate in 2 hours of testing
             with short breaks.

          -  Subjects need to be able to provide informed consent.

        Exclusion Criteria:

          -  Any substantial decrease in alertness, language reception, or attention that might
             interfere with understanding instruction for motor testing

          -  Excessive pain in any joint of the paretic extremity (not applicable to severe stroke
             subjects), as self reported

          -  Contraindications to single pulse TMS (will be used to measure cortical excitability)
             such as: history of seizures, unexplained loss of consciousness, any metal implants in
             the head, frequent or severe headaches or neck pain, any other electronic implanted
             medical devices such as pacemakers, defibrillators, or implant medication pump.

          -  Patients who have taken fluoxetine in the past 5 weeks.

          -  Patients taking any other SSRI at the time of enrollment or in the previous month.

          -  Patients taking any other medication likely to have adverse interaction with SSRIs
             (all the medications the patient is taking will be carefully reviewed, as noted below
             in &quot;Monitoring of important drug interactions&quot;).

          -  Active depression on admission to SRH defined by a score of 24 or higher in the
             Hamilton Depression Rating Scale (HAM-D)

          -  Concurrent medical condition likely to worsen patient's functional status in the next
             6 months such as: cancer, terminal heart, kidney or liver disease, as self-reported
             and/or confirmed by medical record.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Fregni, MD PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Rehabilitation Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Rehabilitation Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>August 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spaulding Rehabilitation Hospital</investigator_affiliation>
    <investigator_full_name>Felipe Fregni</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>repetitive transcranial magnetic stimulation</keyword>
  <keyword>rTMS</keyword>
  <keyword>TMS</keyword>
  <keyword>fluoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

